Skip to main content
Terug
Watch Compare

Calidi Biotherapeutics, Inc.

Datakwaliteit: 83%
Ook genoteerd als CLDWW NYSE
CLDI
NYSE Manufacturing Chemicals
€ 0,26
▼ € 0,00 (-0,43%)
Marktkapitalisatie: 2,82 M
Prijs
€ 0,26
Marktkapitalisatie
2,82 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Debt/Equity of 0,09 — conservative balance sheet
Negative free cash flow of -21,29 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-458,56%
Onder sectorgemiddelde (-53,47%)
ROIC-249,18%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,09
Onder sectorgemiddelde (0,30)
Current Ratio2,12
Interest Coverage-202,40

Waardering

PE (TTM)
-0,14
Boven sectorgemiddelde (-1,48)
P/B Ratio0,41
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,1 -1,5
P/B 0,4 1,6
ROE % -458,6 -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E 0,1 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q32025 -€ 1,68 -€ 2,21 -31,5%
Q22025 -€ 1,32 -€ 1,99 -51,0%
Q12025 -€ 1,80 -€ 2,25 -24,8%
Q42024 -€ 4,44 -€ 3,24 +27,0%

ETFs Holding This Stock

BRSIX BRSIX
0,01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -19,91 M
ROE -458,56% ROA -170,28%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -21,29 M
ROIC -249,18% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,09 Current Ratio 2,12
Interest Coverage -202,40 Asset Turnover N/A
Working Capital 5,84 M Tangible Book Value 6,92 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,14 Forward P/E N/A
P/B Ratio 0,41 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -756,00%
Market Cap 2,82 M Enterprise Value 3,42 M
Per Share
EPS (Diluted TTM) -5,95 Revenue / Share N/A
FCF / Share -1,95 OCF / Share -1,95
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 106,97%
SBC-Adj. FCF -23,64 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2021 FY2022
Revenue — — 45.000,0 — —
Net Income -19,91 M -22,14 M -29,22 M 3,39 M 3,53 M
EPS (Diluted) -5,95 -2,97 1,73 — —
Gross Profit — — — — —
Operating Income -20,24 M -21,78 M -28,99 M -1,78 M -4,67 M
EBITDA — — — — —
R&D Expenses 9,74 M 8,88 M 13,01 M — —
SG&A Expenses 10,50 M 12,90 M 15,98 M — —
D&A 1,65 M — — — —
Interest Expense 100.000,0 700.000,0 1,10 M — —
Income Tax 15.000,0 14.000,0 16.000,0 — 346.987,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2021 FY2022
Total Assets 8,86 M 14,18 M 10,02 M 231,77 M 42,85 M
Total Liabilities 5,10 M 12,21 M 18,25 M 16,45 M 5,61 M
Shareholders' Equity 3,76 M 1,53 M -8,24 M -14,69 M -5,21 M
Total Debt 600.000,0 600.000,0 2,06 M — —
Cash & Equivalents — 9,60 M — 1,06 M —
Current Assets 6,26 M 10,23 M 4,30 M 1,48 M 401.671,0
Current Liabilities 3,94 M 9,50 M 10,23 M 410.985,0 4,54 M